Pfizer Advances Avelumab In Ovarian Cancer With Syndax Combo Deal
This article was originally published in The Pink Sheet Daily
Phase I/II trial will combine Syndax's entinostat, an HDAC inhibitor, with Pfizer/Merck KGaA's PD-L1 inhibitor avelumab. The antibody is the first immunotherapy to reach Phase III in platinum-resistant/refractory ovarian cancer.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.